Abstract
The clinical presentation at the time of diagnosis and the disease course of ulcerative colitis (UC) are heterogeneous and variable over time. In population-based epidemiological follow-up studies from the last decades, the extent of UC has shown only slight variation. At diagnosis, the initial extent is evenly distributed among proctitis, leftsided, and extensive colitis with some exceptions. The disease course may vary from a single attack to chronic symptoms that reduce the quality of life as well as lead to disease extension, colectomy or even to the development of colitisassociated colorectal cancer in some cases. Important predictive clinical factors and biomarkers of disease course have been under increasing scrutiny. Those identified may eventually lead to a more personalized, tailored therapy. In this review article, the authors summarize the available evidence on the natural history and predictive markers for evaluating the course of UC.
Keywords: Ulcerative Colitis, Natural history, UC-CRC, Predictive factors, inflammatory bowel disease, Colectomy, Azathioprine, EC-IBD, Colorectal Cancer, HLA markers, IBSEN, Primary Sclerosing Cholangitis
Current Drug Targets
Title: Natural History of Ulcerative Colitis: Current Knowledge
Volume: 12 Issue: 10
Author(s): Lajos Sandor Kiss and Peter Laszlo Lakatos
Affiliation:
Keywords: Ulcerative Colitis, Natural history, UC-CRC, Predictive factors, inflammatory bowel disease, Colectomy, Azathioprine, EC-IBD, Colorectal Cancer, HLA markers, IBSEN, Primary Sclerosing Cholangitis
Abstract: The clinical presentation at the time of diagnosis and the disease course of ulcerative colitis (UC) are heterogeneous and variable over time. In population-based epidemiological follow-up studies from the last decades, the extent of UC has shown only slight variation. At diagnosis, the initial extent is evenly distributed among proctitis, leftsided, and extensive colitis with some exceptions. The disease course may vary from a single attack to chronic symptoms that reduce the quality of life as well as lead to disease extension, colectomy or even to the development of colitisassociated colorectal cancer in some cases. Important predictive clinical factors and biomarkers of disease course have been under increasing scrutiny. Those identified may eventually lead to a more personalized, tailored therapy. In this review article, the authors summarize the available evidence on the natural history and predictive markers for evaluating the course of UC.
Export Options
About this article
Cite this article as:
Sandor Kiss Lajos and Laszlo Lakatos Peter, Natural History of Ulcerative Colitis: Current Knowledge, Current Drug Targets 2011; 12 (10) . https://dx.doi.org/10.2174/138945011796818117
DOI https://dx.doi.org/10.2174/138945011796818117 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenetic Therapies and Potential Drugs for Treating Human Cancer
Current Drug Targets Development of Novel Combined Time and pH-Dependent based Drug Delivery Systems for Targeting 5-Fluorouracil to the Colon
Current Drug Delivery Click Chemistry, A Potent Tool in Medicinal Sciences
Current Medicinal Chemistry Withdrawal Notice: Electrophoresis as a Tool for Early Cancer Diagnosis
Anti-Cancer Agents in Medicinal Chemistry Deciphering of The Effect of Chemotherapeutic Agents on Human Glutathione S-Transferase Enzyme and MCF-7 Cell Line
Protein & Peptide Letters A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery New Developments of Differentiation Therapy of Acute Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine Hypoxia Inducible Factor-1 in Cancer Immune Suppression
Current Immunology Reviews (Discontinued) Magnetic Nanoparticles: A Review on Stratagems of Fabrication an d its Biomedical Applications
Recent Patents on Drug Delivery & Formulation The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design FEN1 Status and Its Correlation with Clinicopathologic Characteristic in Colorectal Cancer
Combinatorial Chemistry & High Throughput Screening Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery Rational Drug Design for Identifying Novel Multi-target Inhibitors for Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Application of Proteome Analysis to the Assessment of Prognosis and Response Prediction in Clinical Oncology
Current Cancer Drug Targets Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Toxicology of Tributyltin in Mammalian Animal Models
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Application of Molecular Imaging Technologies in Antitumor Drug Development and Therapy
Current Pharmaceutical Design HLA Class I Expression, Tumor Escape and Cancer Progression
Current Cancer Therapy Reviews Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued)